To connect with Syndesi Therapeutics employee register on SignalHire. The Internet site that you have requested may not be optimized to your screen size. Syndesi Therapeutics offers modulators to improve cognition in diseases such as alzheimer's disease and other conditions causing cognitive impairment. The lead molecule, SDI-118, is a small molecule currently in Phase 1b studies, which is being evaluated to target nerve terminals to enhance synaptic efficiency. Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie's acquisition of Allergan plc ("Allergan"), failure to promptly and effectively integrate Allergan's businesses, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19. The deal will expand AbbVie 's neurological . AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. Copyright 2022 AbbVie Inc. North Chicago, Illinois, U.S.A. Syndesi Therapeutics has raised a total of 26.2M in funding over 3 rounds. NORTH CHICAGO, Ill., March 1, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE. I am delighted with the announcement of this deal. There is a major unmet need for new therapies that can . The mechanism is currently being evaluated for the potential treatment of cognitive impairment and other symptoms associated with a range of neuropsychiatric and neurodegenerative disorders, such as Alzheimer's disease and major depressive disorder. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI 118. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. AbbVie will pay Syndesi's shareholders a $130 million upfront payment with the potential for Syndesi's shareholders to receive additional contingent payments of up to $870 million based on the achievement of certain predetermined milestones. "There is a major unmet need for new therapies that can help improve cognitive function in patients suffering from difficult-to-treat neurologic diseases," saidTom Hudson, M.D., senior vice president, R&D, chief scientific officer, AbbVie. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. Address: Centre d'Entreprises et d'Innovation (CEI) Incubator Chemin du Cyclotron 6 1348 Louvain-la-Neuve Belgium. COPENHAGEN, Denmark, March 1, 2022 /PRNewswire/ -- Novo Holdings, a leading international life sciences investor, today announces that its portfolio company Syndesi Therapeutics ('Syndesi'). Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Syndesi was created in 2018 as the result of a close collaboration between Novo Seeds, the company creation arm of Novo Holdings, and UCB Pharma, the Belgium-based global pharmaceutical company . AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. Pipeline Prospector delivers free access to a database of drugs under clinical trials which made headlines done by Syndesi Therapeutics AbbVie, 01 March 2022: AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio.This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its . Brussels, Belgium - February 1st, 2018 - The creation of Syndesi Therapeutics ('Syndesi') was announced today as the result of a partnership between UCB and a syndicate of Belgian and international investors.The investor syndicate is led by Novo Seeds and Fountain Healthcare together with Johnson & Johnson Innovation - JJDC, Inc. (JJDC), V-BIO Ventures, the Walloon Investment Fund . AbbVie announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. On March 1, 2022, the American pharmaceutical giant AbbVie completed the acquisition of the Belgian biotechnology Syndesi Therapeutics. Los Angeles, CA 90025. This is a profile preview from the PitchBook Platform. Find company research, competitor information, contact details & financial data for Syndesi Therapeutics of Ottignies-Louvain-la-Neuve, WALLOON BRABANT. 12401 Wilshire Blvd. Cookie Settings. This area is reserved for members of the news media. Syndesi Therapeutics serves customers worldwide. See insights on Syndesi Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. "We have been impressed with the vision of AbbVie's neuroscience R&D team, who share our view on the therapeutic potential of SDI-118 in a range of neurologic diseases," said Jonathan Savidge, chief executive officer, Syndesi Therapeutics. "We have been impressed with the vision of AbbVie's neuroscience R&D team, who share our view on the therapeutic potential of SDI-118 in a range of neurologic diseases," said Jonathan Savidge, chief executive officer, Syndesi Therapeutics. Novo Holdings and Fountain Healthcare Partners are the most recent investors. Solutions. Under the terms of the agreement, AbbVie will pay Syndesi shareholders a $130 million upfront payment with the potential for Syndesi shareholders to receive additional contingent payments of up to $870 million based on the achievement of certain predetermined milestones. The mechanism is currently . 1348 Louvain-la-Neuve | Now, as part of AbbVie, the program is well positioned to move into later stages of clinical development.". AbbVie announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. It has been a pleasure to partner with our investors to investigate the potential of SDI-118 in early clinical studies. With an upfront payment of $130 million, AbbVie gains Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. Syndesi Therapeutics has exclusively licensed a first-in-class small molecule program from UCB and the series A investment totalling 17M will fund the clinical development of the lead compound up to early proof-of-concept in humans. AbbVie has bolstered its neuropsychiatric and neurodegenerative portfolio with the acquisition of Belgium-based Syndesi Therapeutics in a deal valued at up to $1 billion. Jonathan Savidge, Chief Executive Officer, Syndesi Therapeutics, said: "We have been impressed with the vision of AbbVie's neuroscience R&D team, who share our view on the therapeutic potential of SDI-118 in a range of neurologic diseases. Their latest funding was raised on Sep 28, 2020 from a Series A round. Find More Contacts for Syndesi Therapeutics, Edit Lists Featuring This Company Section, Novo Holdings Portfolio Company Syndesi Therapeutics acquired by AbbVie, Syndesi Therapeutics Announces Positive Results From Two Additional Phase I Studies Of Its Novel SV2A modulator SDI-118, Johnson & Johnson Innovation JJDC Portfolio Companies. We are creating a new and unique treatment approach using differentiated bone-forming cells. Syndesi Therapeutics uses 8 technology products and services including HTML5, Google Analytics, and Microsoft Outlook, according to G2 Stack. Syndesi Therapeutics's Chief Executive Officer is Jonathan Savidge. In addition to Syndesi Therapeutics Novo Seeds has launched four other companies in the neuroscience space including Muna Therapeutics (neurodegeneration), NMD Pharma (neuromuscular disorders), Hoba Therapeutics (Pain), and Avilex Pharma (Acute Ischemic Stroke). Description. Follow @abbvie on Twitter, Facebook, Instagram, YouTubeand LinkedIn. We are harnessing science to improve connections on many levels. The company's drugs can modulate the synaptic vesicl, eu fugiat nulla pariatur. Get the full list. Syndesi's unique molecules act pre-synaptically to enhance synaptic efficiency by . The lead molecule, SDI-118, was discovered by UCB before being out-licensed to Syndesi as of 2018. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. The North Chicago-based pharmaceutical giant (NYSE: ABBV . NORTH CHICAGO, Ill., March 1, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. The mechanism is currently being evaluated for the potential treatment of cognitive impairment and other symptoms associated with a range of neuropsychiatric and neurodegenerative disorders, such as Alzheimer's disease and major depressive disorder. Ut enim ad min, To view Syndesi Therapeuticss complete valuation and funding history, request access, To view Syndesi Therapeuticss complete cap table history, request access, Youre viewing 5 of 50 competitors. UCB identified novel modulators of SV2A that show pro-cognitive properties in preclinical models. The mechanism is currently being evaluated for . Syndesi Therapeutics is funded by 9 investors. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie. All rights reserved. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its . Regulating synaptic transmission represents a promising approach to treating Alzheimer's Disease and other disorders with cognitive impairment. Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research. Syndesi Therapeutics is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment seen in multiple CNS disorders, including Alzheimers Disease, schizophrenia and depresson. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. - Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies. "I am delighted with the closing of this deal. Funding Rounds Number of Funding Rounds 3 Total Funding Amount 26.2M AbbVie has bolstered its neuropsychiatric and neurodegenerative portfolio with the acquisition of Belgium-based Syndesi Therapeutics in a deal valued at up to $1 billion. | With our robust radiopharmaceutical production and distribution network, mature contract manufacturing services, and now, high value radiopharmaceutical intellectual property, we are poised to deliver on the promise of . No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company. Syndesi Therapeutics is developing molecules which act in a unique way on the synaptic vesicle protein SV2A. UCB spins out neuro startup with 17M from Novo, Johnson & Johnson Syndesi Therapeutics. Privacy policy The information in the press releases on these pages was factually accurate on the date of publication. Name of the organization that made the acquisition, Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Total number of organizations similar to the given organization, Descriptive keyword for an Organization (e.g. Westside Therapeutics Westside Therapeutics Westside Therapeutics. Synaptic dysfunction is believed to underlie the cognitive impairment seen in multiple neuropsychiatric and neurodegenerative disorders. Sign up Active, Closed, Last funding round type (e.g. Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. Developer of drug molecules designed to treat cognitive impairment. 01 Mar 2022. Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. Syndesi Therapeutics has 5 employees across 2 locations and $21.13 m in total funding,. "With AbbVie's acquisition of Syndesi, we aim to advance the research of a novel, first-in-class asset for the potential treatment of cognitive impairment associated with neuropsychiatric and neurodegenerative disorders.". Products. For more information about AbbVie, please visit us atwww.abbvie.com. 17,000,000 Venture capital (Series A) FierceBiotech. A regenerative therapy company - Bone Therapeutics. Use Slintel to connect with top decision-makers at Syndesi Therapeutics. Syndesi was created through a partnership between UCB Biopharma SRL and a syndicate of Belgian and international investors to further develop novel SV2A modulators that had been originally discovered by UCB. They are also entitled to get further contingent payments of up to $870m on meeting specific pre-set milestones. UCB identified novel modulators of SV2A that show pro-cognitive properties in preclinical models. 2022 PitchBook. AbbVie has acquired Belgium-based company Syndesi Therapeutics in a deal worth up to $1bn, expanding its neuroscience portfolio.. | For further information AbbVie assumes no duty to update the information to reflect subsequent developments.